Arterial infusion of rapamycin in the treatment of rabbit hepatocellular carcinoma to improve the effect of TACE
Open Access
- 1 January 2018
- journal article
- research article
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 13 (1) , 299-304
Abstract
Background: Hepatocellular carcinoma is one of the leading causes of cancer-related death. Hepatic transcatheter arterial chemo-embolization (TACE) is commonly used clinically for advanced hepatocellular carcinoma treatment. AIM: The aim of this study was to evaluate whether arterial infusion of rapamycin can improve the effect of TACE in treatment of rabbit hepatocellular carcinoma. Material and Methods: Eighteen healthy New Zealand white rabbits weighing 2.6 ± 0.3 kg were used in a standardised hepatocellular carcinoma model and randomly divided into three groups of 6 rabbits. Group A: the rabbits were treated with rapamycin and TACE by administering arterial perfusion of 2 mg/kg rapamycin + 1 mg/kg epirubicin, 0.2 mg/kg mitomycin, and lipiodol emulsion embolization. Group B: rapamycin was reduced to 1 mg/kg. And for Group C, the rabbits received only TACE treatment. 14 days post operation, CT scan and digital subtraction angiography (DSA) was performed to examine TACE efficacy. The rabbits were killed by air embolism and the expression of HIF-1a, VEGF, iNOS, and CD34 were measured in an immunohistochemical assay of thetumor tissue. Results: HIF-1a, VEGF and iNOS protein expression in Group A was significantly lower than that of Group B and Group C (P<0.05). The tumor MVD in group C was significantly higher than that of group A and group B (P<0.05); and the tumor MVD of group B was significantly higher than group A (P<0.05). Conclusion: Arterial infusion of rapamycin combined with TACE can improve treatment efficacy by decreasing HIF-1a, VEGF, iNOS and CD34 expression.Keywords
This publication has 20 references indexed in Scilit:
- Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular CarcinomaThe Scientific World Journal, 2013
- Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: Molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vesselsLasers in Surgery and Medicine, 2012
- Rapamycin inhibits transforming growth factor β‐induced peritoneal angiogenesis by blocking the secondary hypoxic responseJournal of Cellular and Molecular Medicine, 2011
- Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic AdenocarcinomaGut and Liver, 2010
- Mammalian Target of Rapamycin Pathway Promotes Tumor-Induced Angiogenesis in Adenoid Cystic Carcinoma: Its Suppression by Isoliquiritigenin through Dual Activation of c-Jun NH2-Terminal Kinase and Inhibition of Extracellular Signal-Regulated KinaseThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Impact of rapamycin on liver regenerationVirchows Archiv, 2008
- Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methodsLaboratory Animals, 2004
- The FKBP12‐rapamycin‐associated protein (FRAP) is a CLIP‐170 kinaseEMBO Reports, 2002
- FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunctionProceedings of the National Academy of Sciences, 2002
- Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycin–Associated Protein–Mediated P53 PhosphorylationJournal of Experimental Medicine, 2001